The National Pharmaceutical Pricing Authority (NPPA) announced on 28 October 2026 that it has released revised Maximum Retail Prices (MRP) for 543 brands of anti-cancer medicines. These new prices are part of an effort to make cancer treatment more affordable by addressing excessive trade margins. The revised prices will take effect from 9 November 2026. The list will be updated continually as manufacturers submit revised prices for non-scheduled anti-cancer drugs.
Key points
- Effective 9 Nov 2026: Revised MRPs for 543 anti-cancer medicine brands apply
- Goal: Make cancer treatment more affordable and improve access to medicines
- Scope: Includes immunotherapy drugs and medicines for breast, prostate, colon, ovarian, and cervical cancers
- Updates: The NPPA portal will be updated continually as manufacturers submit new prices
When it applies
- Revised MRPs for anti-cancer medicines
- announcement of Trade Margin Rationalisation (TMR) of 137 non-scheduled anti-cancer drugs
Who it affects
- 543 brands of anti-cancer medicines